Synonyms: Compound A [WO2022237720]
Compound class:
Synthetic organic
Comment: The structure for bleximenib was obtained from proposed INN list 129 (August 2023). This maps to a PubChem CID that describes it as a menin-mixed-lineage leukemia 1 (menin-MLL) inhibitor. The compound is claimed in patent WO2022237720A1 (Janssen, Johnson & Johnson), for potential to treat hematological malignancies (in combination with a BCL-2 inhibitor) [1]. This class of agents disrupts the interaction between MLL oncoproteins (re-arranged MLL fusion proteins that are found in aggressive human acute leukemias) and the tumour suppressor protein menin (MEN1, O00255). Menin is an essential oncogenic co-factor for the leukemogenicity of MLL fusion proteins.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
N-ethyl-5-fluoro-2-[[5-[2-[(3R)-6-[2-methoxyethyl(methyl)amino]-2-methylhexan-3-yl]-2,7-diazaspiro[3.4]octan-7-yl]-1,2,4-triazin-6-yl]oxy]-N-propan-2-ylbenzamide |
Synonyms |
Compound A [WO2022237720] |
Database Links | |
GtoPdb PubChem SID | 485205987 |
PubChem CID | 156498110 |
Search Google for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |
Search Google for chemicals with the same backbone | PDUGAXSIWNMIBQ |
UniChem Compound Search for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | PDUGAXSIWNMIBQ-HHHXNRCGSA-N |